<DOC>
	<DOCNO>NCT02142868</DOCNO>
	<brief_summary>To provide access palbociclib post-menopausal woman HR-positive , HER2-negative advance breast cancer deem appropriate letrozole therapy ( Canada : first-line patient ) .</brief_summary>
	<brief_title>Expanded Access Study Of Palbociclib ( PD-0332991 ) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive , Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate</brief_title>
	<detailed_description>This study currently available Canada .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman 18 year age proven diagnosis advance adenocarcinoma breast ( locoregionally recurrent metastatic disease ) ERpositive and/or PRpositive tumor base local laboratory result HER2negative tumor base local laboratory result Patients must appropriate candidate letrozole therapy ( Canada : firstline patient ) Patients previously participate palbociclib trial receive prior treatment CDK inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Expanded Access</keyword>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>